Yearly Archives : 2012

Enablers of drug innovation could lie in the numbers

Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem. Recent developments in the pharmaceutical industry are encouraging drug developers to re-think their strategies toward innovation and development. The expiration of blockbuster patents and the subsequent…